CEbiotech.com - Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Supergenerics - Pharma’s freshmaker!

Supergenerics - Pharma’s freshmaker!

Publish date: 2012-12-06

‘Boring’ white pills no longer do the trick from a marketing point of view. Furthermore governments and payers are looking at reducing the prices of the drugs as the way to contain costs. Additionally, margins of drugs are falling. Because of these two reasons there is a strong competition among commodity generics.

Tags: bioforum , events , pharma

A traditional generic drug is essentially the same as the original drug, incorporating the active pharmaceutical ingredient (API) for which the patent has expired. It is typically approved through a simplified registration process and then sold under a common, rather than brand, name. In a typical generics market scenario, a drug goes off patent and competitors rapidly penetrate the market within weeks. This results in a significant price decrease, the product becomes a commodity, and the original drug maker suffers a sharp loss of market share and revenues. Taking into consideration all those facts, it is not surprising that generic drug manufacturers are looking at innovation to get to the next big league - 'supergenerics'.

 

The term “supergeneric” has been given to the development process for small molecule drugs which offer a therapeutic advantage or differ from commodity generic products. While commodity generics are clones of the original drug, supergenerics represent new therapeutic entities that demonstrate improvements in methods of delivery, formulation, design or the manufacturing process. In fact, a supergeneric will sometimes need a completely new drug application in order to gain approval from the Food and Drug Administration (FDA).

 

On the other hand supergenerics may be able to offer a low-risk, low-cost alternative to the traditional pharmaceutical development of new medicines, due to their shorter development timeline. New Chemical Entities (NCEs) take a long time to develop, often exceeding the cost of $1billion. Conversely, the development of a supergeneric is more comparable to that of a generic compound, as it has a known mechanism of action and an established safety and efficacy profile.

 

Since 2004, over 245 drugs have been approved in the US, of which 70% were novel formulations and 18% were new combinations. There are currently more than 60 novel supergeneric formulations of approved oncology, CNS, pain and respiratory products undergoing development (source: GBI Research).

Because of simpler delivery system, supergenerics are more friendly for patient, thus more willingly to use for them, for instance - delivery via oral or patches, instead of injections. These methods are not only simple but also increase effectiveness. Furthermore, supergenerics can be prepared in such way, that active ingredient is liberated in longer time in comparison to generics. It causes that patient takes medicines more rarely than in case of generics.

 

Nowadays, the “One‐fits all“ trend dominates. The change in the demographic composition as well as the growing demand from the pharmerging markets will create a substantial need for individualized therapeutic solutions that could be addressed by developing patient centered pharmaceutical products through “supergeneric” route. Thus increasing the therapeutic results of drug therapy and support the efficient use of healthcare resources.

 

Supergenerics are an important source for innovation in drug therapy in the coming decades.

This topic under the name “Innovation in generics” will be widely discussed on the BioForum 2013 in Budapest. The panel will focus on presenting CEE innovation potential, including the generic market which in CEE  covers over 95% of the pharma industry.

 

BioForum - Central European Forum of Biotechnology & Innovative BioEconomy and the accompanying events will take place on 22-23rd May 2013 in Budapest. The originator and the main organizer of this event is a polish company: Bio‑Tech Consulting (www.biotechconsulting.eu).


‘Boring’ white pills no longer do the trick from a marketing point of view. Furthermore governments and payers are looking at reducing the prices of the drugs as the way to contain costs. Additionally, margins of drugs are falling.  Because of these two reasons there is a strong competition among commodity generics.

A traditional generic drug is essentially the same as the original drug, incorporating the active pharmaceutical ingredient (API) for which the patent has expired. It is typically approved through a simplified registration process and then sold under a common, rather than brand, name. In a typical generics market scenario, a drug goes off patent and competitors rapidly penetrate the market within weeks. This results in a significant price decrease, the product becomes a commodity, and the original drug maker suffers a sharp loss of market share and revenues. Taking into consideration all those facts, it is not surprising that generic drug manufacturers are looking at innovation to get to the next big league - 'supergenerics'.

 

The term “supergeneric” has been given to the development process for small molecule drugs which offer a therapeutic advantage or differ from commodity generic products. While commodity generics are clones of the original drug, supergenerics represent new therapeutic entities that demonstrate improvements in methods of delivery, formulation, design or the manufacturing process. In fact, a supergeneric will sometimes need a completely new drug application in order to gain approval from the Food and Drug Administration (FDA).

 

On the other hand supergenerics may be able to offer a low-risk, low-cost alternative to the traditional pharmaceutical development of new medicines, due to their shorter development timeline. New Chemical Entities (NCEs) take a long time to develop, often exceeding the cost of $1billion. Conversely, the development of a supergeneric is more comparable to that of a generic compound, as it has a known mechanism of action and an established safety and efficacy profile.

 

Since 2004, over 245 drugs have been approved in the US, of which 70% were novel formulations and 18% were new combinations. There are currently more than 60 novel supergeneric formulations of approved oncology, CNS, pain and respiratory products undergoing development (source: GBI Research).

Because of simpler delivery system, supergenerics are more friendly for patient, thus more willingly to use for them, for instance - delivery via oral or patches, instead of injections. These methods are not only simple but also increase effectiveness. Furthermore, supergenerics can be prepared in such way, that active ingredient is liberated in longer time in comparison to generics. It causes that patient takes medicines more rarely than in case of generics.

 

Nowadays, the “One‐fits all“ trend dominates. The change in the demographic composition as well as the growing demand from the pharmerging markets will create a substantial need for individualized therapeutic solutions that could be addressed by developing patient centered pharmaceutical products through “supergeneric” route. Thus increasing the therapeutic results of drug therapy and support the efficient use of healthcare resources.

 

Supergenerics are an important source for innovation in drug therapy in the coming decades.

This topic under the name “Innovation in generics” will be widely discussed on the BioForum 2013 in Budapest. The panel will focus on presenting CEE innovation potential, including the generic market which in CEE  covers over 95% of the pharma industry.

 

BioForum - Central European Forum of Biotechnology & Innovative BioEconomy and the accompanying events will take place on 22-23rd May 2013 in Budapest. The originator and the main organizer of this event is a polish company: Bio‑Tech Consulting (www.biotechconsulting.eu).

 

More on: www.cebioforum.com

Comments:

Add comment
Guest
2016-04-03 06:25:05 +0200
My name is Jessica Luis, and I base in USA...My life is back!!! After 1 years of Broken marriage, my husband left me with two kids . I felt like my life was about to end i almost committed suicide, i was emotionally down for a very long time. Thanks to a spell caster called Dr Mohammed, which i met online. On one faithful day, as I was browsing through the internet,I came across allot of testimonies about this particular spell caster. Some people testified that he brought their Ex lover back, some testified that he restores womb,cure cancer,and other sickness, some testified that he can cast a spell to stop divorce and so on. i also come across one particular testimony,it was about a woman called Sonia,she testified about how he brought back her Ex lover in less than 2 days, and at the end of her testimony she dropped Dr Mohammed's e-mail address. After reading all these,I decided to give it a try. I contacted him via email and explained my problem to him. In just 48hours, my husband came back to me. We solved our issues, and we are even happier than before Dr Mohammed, is really a gifted man and i will not stop publishing him because he is a wonderful man... If you have a problem and you are looking for a real and genuine spell caster to solve all your problems for you. Try High monicaspiritualtemple@gmail.com anytime, he might be the answer to your problems. Here's his contact: monicaspiritualtemple@gmail.com or call him +2348134493948
Guest
2016-04-03 04:14:29 +0200
'After being in relationship with Wilson for seven years,he broke up with me, I did everything possible to bring him back but all was in vain, I wanted him back so much because of the love I have for him, I begged him with everything, I made promises but he refused. I explained my problem to someone online and she suggested that I should contact a spell caster that could help me cast a spell to bring him back but I am the type that don't believed in spell, I had no choice than to try it, I meant a spell caster called Dr Zuma zuk and I email him, and he told me there was no problem that everything will be okay before three days, that my ex will return to me before three days, he cast the spell and surprisingly in the second day, it was around 4pm. My ex called me, I was so surprised, I answered the call and all he said was that he was so sorry for everything that happened, that he wanted me to return to him, that he loves me so much. I was so happy and went to him, that was how we started living together happily again. Since then, I have made promise that anybody I know that have a relationship problem, I would be of help to such person by referring him or her to the only real and powerful spell caster who helped me with my own problem and who is different from all the fake ones out there. Anybody could need the help of the spell caster, his email: spiritualherbalisthealing@gmail.com or call him +2349055637784 you can email him if you need his assistance in your relationship or anything. CONTACT HIM NOW FOR SOLUTION TO ALL YOUR PROBLEMS'
See also
For already 11 years, the BioForum trade fair (www.cebioforum.com) has been attracting to Łódź, the centre of ... Read more
Tags: czech republic , bioforum
Central Europe (CE) is an emerging biotech market, a small star among European regions. There are more or less ... Read more
Tags: biotechnology , bioforum
HAYS Czech Republic, leading global experts in qualified in professional and skilled recruitment, joints to Bio... Read more
Tags: czech republic , bioforum